Effect of melatonin and melatonin agonists on postoperative sleep quality in adult patients: a protocol for systematic review and meta-analysis with trial sequential analysis

Akito Tsukinaga, Takahiro Mihara, Teppei Takeshima, Makoto Tomita, Takahisa Goto, Takeharu Yamanaka

ABSTRACT

Introduction The circadian rhythm of melatonin secretion is disturbed after general anaesthesia, leading to postoperative sleep disturbance. Small studies investigating the preventive effect of melatonin administration on postoperative sleep disturbance have not reached any conclusions. Therefore, we will conduct a systematic review and meta-analysis to obtain conclusive results.

Methods and analysis We prepared this protocol following the 2015 Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols guidelines. We will conduct a search for randomised controlled trials that evaluated the effect of melatonin and melatonin agonists on postoperative sleep quality in adult patients undergoing general anaesthesia or regional anaesthesia with sedation. We will exclude patients undergoing regional anaesthesia without sedation. Relevant studies will be searched in the following eight databases: MEDLINE, the Cochrane Central Register of Controlled Trials, Embase, Web of Science and four preregistration sites from inception to 1 January 2021. No language restrictions will be applied. Two authors will independently scan and select eligible studies and perform data extraction and assessment of the risk of bias. The Visual Analogue Scale scores for sleep quality will be combined as the mean difference with a 95% CI using a random-effect model; we will use I² to assess heterogeneity. We will evaluate the quality of trials using the Cochrane methodology and assess the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. If appropriate, trial sequential analysis will be performed.

Ethics and dissemination No ethical approval is required for this meta-analysis, as it does not include individual patient data. We will disseminate the results of this meta-analysis in a peer-reviewed journal.

PROSPERO registration number CRD42020180167.

INTRODUCTION

Description of the condition Postoperative sleep disturbance is common. Although pain is one of the most important contributing factors, patients with low postoperative pain levels also suffer from poor sleep quality. Postoperative sleep disturbance is also associated with subsequent cognitive dysfunction, and the importance of its prevention is drawing attention. In response, there is an expert consensus that postoperative sleep quality is one of the patient outcomes to be studied during the postoperative period.

Description of the intervention and how the intervention may work

The intervention of interest is the postoperative administration of melatonin or melatonin agonists, compared with placebo or no intervention. Melatonin is a central circadian regulator, primarily produced by the pineal gland and a normal melatonin rhythm is partly instrumental in the regulation of the sleep-wake cycle. Melatonin is also known...
to have an excellent safety profile and has no major adverse effects such as respiratory depression. The circadian rhythm of melatonin secretion is disturbed after surgery, and this disturbance is thought to contribute to postoperative sleep disturbance.

Why is it important to perform this review?
Small studies investigating the preventive effect of melatonin administration on postoperative sleep quality have not reached any conclusion. Therefore, a systematic review and meta-analysis of these small studies could add value to our current knowledge of postoperative melatonin administration.

Zhang et al conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) and suggested that melatonin intervention shows no significant influence on sleep quality compared with a control group. However, since they limited the surgery to laparoscopic cholecystectomy and analysed only two RCTs for sleep quality, their conclusion may be underpowered. In this systematic review, we will include all types of surgery. Moreover, we will conduct a subgroup analysis to reveal the pivotal factors affecting the effects of melatonin and melatonin agonists on sleep quality.

Objectives
The primary purpose of this meta-analysis is to assess the Visual Analogue Scale (VAS) scores for sleep quality compared with no treatment or placebo. Secondary purposes are to assess sleep quality evaluated using other specific tools and adverse events. When significant heterogeneity is found, we will conduct subgroup analyses based on the following predefined factors:
1. Type of anaesthesia (regional anaesthesia, inhaled general anaesthesia and total intravenous general anaesthesia).
2. Surgery type.
3. Timing of surgery (daytime vs nighttime).
4. Drug type (melatonin vs melatonin agonists).
5. Dose of melatonin/melatonin agonists.
6. Age.
7. Type of control (placebo vs no treatment).

METHODS AND ANALYSIS
This protocol follows the guidelines according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA). We will use the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions.

Eligibility criteria
Study designs
We will include all RCTs that tested the effect of melatonin or melatonin agonists on postoperative sleep quality in adult patients undergoing regional or general anaesthesia. We will exclude data from case reports, observational studies, reviews and animal studies.

Participants
We will include studies examining adults (≥18 years) undergoing general anaesthesia or regional anaesthesia with sedation for any surgery. We will exclude patients undergoing regional anaesthesia without sedation. Eligibility will not be restricted by language, type of surgery or type of anaesthesia.

Interventions
The intervention of interest will be the perioperative (7 days before and after the date of surgery) administration or therapy duration. There will be no restrictions based on dosing, frequency, timing, route of administration or therapy duration.

Comparators
We will include no treatment or placebo as control interventions.

Information sources and search strategy
We will conduct a search in MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE and Web of Science. The reference lists of the relevant articles will be also searched. Further, we will conduct a search of ClinicalTrials.gov, WHO International Clinical Trials Registry Platform and the UMIN Clinical Trials Registry. The literature search will be limited to human subjects. The search strategy combining free text and Medical Subject Headings terms for PubMed is shown in table 1.

Study records
Data management and selection
Two authors (AT and TT) will independently scan the titles and abstracts of reports identified by the search strategies described above. We will use Mendeley to remove duplicate titles and abstracts from our database search. We will export the remaining titles and abstracts to the Rayyan application for screening titles and abstracts. If eligibility cannot be determined from the title or abstract, the full paper will be retrieved. Potentially relevant studies, chosen by at least one author, will be retrieved and evaluated in full-text versions. Articles that meet the inclusion criteria will be assessed independently by two authors, and any discrepancies will be resolved through discussion.

Data collection
Two authors (AT and TT) will extract data independently and in duplicate from each eligible study. To ensure consistency across reviewers, we will conduct calibration exercises before starting the review. Data abstracted will include demographic information, methodology, intervention details and all reported patient-important outcomes. Reviewers will resolve the disagreements by discussion. We will contact the study authors to resolve any uncertainties.

Data items
A data collection sheet will be created and will include data on participants (eg, age, sex, American Society of
Anesthesiologists-physical status), type of anesthesia (regional anesthesia, inhalated general anesthesia and total intravenous general anesthesia), type of surgery (including whether laparoscopic or open surgery), duration of surgery, drug treatment (type, timing, dose and duration of administration), type of control (placebo or no treatment), trial size, duration of follow-up, type and source of financial support and publication status from trial reports. If the actual numbers are provided, we will use them for the analysis. If the actual numbers are not provided, we will use the values originally provided as percentages or numbers of patients, we will measure the lengths of the graphics to obtain the percentages or numbers of patients. Two authors will extract the data independently from the included studies and then cross-check the data.

### Outcomes and prioritisation

#### Primary outcome

The primary outcome will be the sleep quality measured with the VAS during the early postoperative period (ie, between the day after surgery and 3 days after surgery). If the outcomes are measured several times during the early postoperative period, we will use the mean value as the primary outcome.

The VAS consists of a line, which is often 10 cm long. The patient places a mark at a point on the line corresponding to their rating of sleep quality the previous night (0 mm=best conceivable sleep and 100 mm=worst conceivable sleep). When VAS measurements are shorter or longer than 10 cm, they will be scaled to a VAS of 10 cm in length. When the VAS score is defined as 0 mm as the best and 100 mm as the worst conceivable sleep, the scale will be reversed by 100 minus the reported VAS score so that 0 mm is the best conceivable sleep.

#### Secondary outcomes

The secondary outcomes will be as follows:

1. **Sleep-onset latency (minutes).**
2. **Total sleep time (minutes).**
3. **Sleep interruption: number of awakenings and waking after sleep onset.**
4. **Sleep efficiency: percentage of time spent in bed asleep.**
5. **Sleep quality measured other than VAS during the early postoperative period.** We anticipate that there will be studies using the total score of the Richards-Campbell Sleep Questionnaire (RCSQ). Nevertheless, we did not limit our secondary outcomes to the RCSQ and included studies that assessed sleep quality using other methods. If there are studies using scores other than the RCSQ, we will synthesise these scores separately. When the outcomes are measured several times during the early postoperative period, we will adopt the first measured outcome for our primary outcome.
6. **Sleep quality measured with VAS 1 week after surgery (postoperative days 4–10) and 1 month after surgery (following the period defined by each author).**
7. **Sleepiness during the daytime measured with validated questionnaires, such as the Karolinska Sleepiness Scale (KSS) or Stanford Sleepiness Scale (SSS).** If there are studies using scores other than KSS or SSS, we will synthesise these scores separately.
8. **Quality of recovery assessed by validated assessment tool scores such as QoR-40.**
9. **Opioid consumption: cumulative dose (milligram) of intravenous morphine or morphine equivalent.**
10. **Pain assessed by validated assessment tool scores such as VAS, Numerical Rating Scale and Verbal Categorical Rating Scale.**
11. **Any adverse events such as dizziness, desaturation event or delayed recovery.**

### Table 1 Search strategy for PubMed

<table>
<thead>
<tr>
<th>Number</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>#3</td>
<td>“anesthesia”[MeSH Terms] OR “anaesthesia”[Title/Abstract] OR “anesthesia”[Title/Abstract] OR “anaesthetic”[Title/Abstract] OR “anaesthetic”[Title/Abstract]</td>
</tr>
<tr>
<td>#4</td>
<td>(“randomized controlled trial”[Publication Type] OR “controlled clinical trial”[Publication Type]) OR “randomized”[Title/Abstract] OR “placebo”[Title/Abstract] OR “drug therapy”[MeSH Subheading] OR “randomly”[Title/Abstract] OR “trial”[Title/Abstract] OR “groups”[Title/Abstract] NOT (“animals”[MeSH Terms] NOT “humans”[MeSH Terms])</td>
</tr>
<tr>
<td>#5</td>
<td>#1 AND (#2 OR #3) AND #4</td>
</tr>
</tbody>
</table>
The RCSQ is a brief 5-item questionnaire used to evaluate perceived sleep depth, sleep latency (time to fall asleep), number of awakenings, efficiency (percentage of time awake) and sleep quality. Each RCSQ response was recorded on a 100mm VAS, with higher scores representing better sleep and the mean score of these five items, known as the ‘total score’, representing the overall perception of sleep.

Sleep-onset latency, total sleep time, sleep interruption and sleep efficiency are noted in a sleep diary or measured by actigraphy. Actigraphy evaluates rest and activity by algorithmically processing gross motor activity data, usually collected by a non-invasive wristwatch-like accelerometer device.

Sleepiness during day time was measured using the following validated questionnaires: KSS20 or SSS.21 The KSS and the SSS are Likert scales to measure the subjective level of sleepiness at a particular time during the day. On this scale, subjects indicate which level best reflects the psychophysical state. The KSS is a 9-point scale from ‘very alert’ to ‘very sleepy’, fighting sleep, an effort to keep awake’, ‘the SSS is a seven-point scale from ‘very alert’ to ‘completely exhausted, cannot function efficiently’.

Risk of bias of individual studies
We will assess the risk of bias using Cochrane’s Risk of Bias tool (RoB 2) for RCTs.24 The RoB 2.0 assessment for individually randomised trials (including cross-over trials) has five domains and one overall risk of bias domain, as follows:
1. Bias arising from the randomisation process.
2. Bias due to deviations from intended interventions.
3. Bias due to missing outcome data.
4. Bias in the measurement of outcome.
5. Bias for selection of the reported result.
6. Overall risk of bias.

The risk of bias will be assessed as ‘low’, ‘some concern’ or ‘high’ in each domain.

Data synthesis
Statistical analyses will be performed using R software (We will use the newest version at the time of analysis: R Development Core Team, Vienna, Austria) and RStudio (We will use the newest version at the time of analysis: RStudio, Boston, Massachusetts, USA). Continuous data will be summarised using the mean difference (MD) or the standardised mean difference (SMD) with a 95% CI. Dichotomous data will be summarised using the risk ratio with a 95% CI. If the 95% CI includes a value of 0 or 1 for continuous or dichotomous data, respectively, we will consider the difference not to be statistically significant. When there are missing data, we will attempt to contact the original authors of the study to obtain the relevant missing data. Heterogeneity will be quantified using the I² statistic and Cochran’s Q statistic. We will consider that significant heterogeneity exists when the I² statistic exceeds 50%. We will conduct a subgroup analysis to explore the possible causes in cases of high heterogeneity. We will use either a random-effects model (DerSimonian and Laird methods25) or a fixed-effect model, considering clinical and methodological heterogeneity, to combine the results. Forest plots will be used to graphically represent and evaluate the effects of treatment.

We plan to conduct a subgroup analysis according to the following predefined factors when the I² statistic exceeds 50%: (1) type of anaesthesia (regional anaesthesia, inhaled general anaesthesia and total intravenous general anaesthesia), (2) type of surgery, (3) timing of surgery (daytime vs night-time), (4) drug type (melatonin vs melatonin agonists), (5) dose of melatonin/melatonin agonists, (6) age, (7) type of control (placebo vs no treatment) or (8) risk of bias (high risk of bias vs others). Subgroup analysis will not be performed if the number of studies is less than three.

For the primary outcome, trial sequential analysis (TSA) will be performed to correct for random error and repetitive testing of accumulating and sparse data using TSA viewer V.0.9.5.10 β (www.ctu.dk/tsa).26 TSA monitoring boundaries (ie, monitoring boundaries for meta-analysis) and the required information size will be quantified, and the adjusted CIs will be calculated. The risk of type I error will be maintained at 5% with a power of 90%. A 10 mm reduction in MD is considered clinically meaningful. If the cumulative Z-curve does not cross the TSA monitoring boundaries, we will downgrade the quality of evidence owing to inaccuracies in the results.

Reporting bias and publication bias
To determine whether reporting bias is present, we will determine whether the RCT protocol was published before recruitment of patients for the study was initiated. For studies published after 1 July 2005, we will screen the Clinical Trial Register at the ClinicalTrials.gov (https://clinicaltrials.gov/), WHO International Clinical Trials Registry Platform (https://www.who.int临床-trials-registry-platform) and UMIN Clinical Trials Registry (https://www.umin.ac.jp/ctr/). We will evaluate whether selective reporting of outcomes is present (outcome reporting bias) by comparing the outcomes mentioned in the published study protocol or trial registry with the outcomes reported in the paper.

The small study effect will be assessed using a funnel plot and Egger’s regression asymmetry test27 and will be considered positive if p<0.1 in the regression asymmetry test.

Summary of evidence
We will grade the quality of evidence of the main outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach28 29 with the GRADEpro guideline development tool (https://graderpro.org/). Judgements of the quality of evidence will be based on the presence or absence of the following variables: limitations in study design, inconsistency, indirectness, imprecision of the results and publication bias. The quality of evidence for the main outcomes will be graded as very low, low, moderate or high.

Limitation and implications
There are several tools for measuring postoperative sleep quality. The primary outcome will be the sleep quality measured by the VAS, which is considered to be the most...
common assessment tool, but the number of studies that can be synthesised may be small. To compensate for this, we plan to synthesise other assessment tools as a secondary outcome. However, different measurement tools may not necessarily be assessing the same thing, and the conclusions reached, in that case, may be misleading.

The findings from this meta-analysis will indicate whether melatonin and melatonin agonists improve postoperative sleep quality in adult patients undergoing general anaesthesia. In addition, it may reveal the pivotal factors affecting the effects of melatonin and melatonin agonists on sleep quality. If the findings from this meta-analysis are inconclusive, they may help generate new hypotheses and contribute to the design of new RCTs.

Ethics and dissemination
The data used do not include individual patient data, and thus, there are no patient privacy concerns. This systematic review will be published in a peer-reviewed journal. Any significant changes to this protocol will be noted with a description of the change, the corresponding rationale and the date of the amendment. The results will also be presented at relevant conferences.

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Contributors
TM drafted the protocol. AT and TM led to the development of the review protocol and drafted the manuscript. TT, MT, TG and TY read all drafts of the manuscript, provided feedback and approved the final manuscript.

Funding
This meta-analysis will be supported by funding from the Department of Anaesthesiology, Yokohama City University, Yokohama, Japan. Award/Grant number is not applicable.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Takahiro Mihara http://orcid.org/0000-0003-0813-511X

REFERENCES